Eu­ro­pean phar­ma group wants to cre­ate PRV-like sys­tem to spur an­tibi­otics R&D

New re­search fund­ed by a Eu­ro­pean phar­ma in­dus­try group is look­ing to rein­vig­o­rate an­timi­cro­bial R&D with a sys­tem that’s sim­i­lar to the pri­or­i­ty re­view vouch­er sys­tems in the US, which spurs new re­search in rare pe­di­atric dis­eases, rare trop­i­cal dis­eases and med­ical coun­ter­mea­sures.

As the need for nov­el an­tibi­otics is ur­gent, EF­PIA is call­ing for a Trans­fer­able Ex­clu­siv­i­ty Ex­ten­sion (TEE) vouch­er sys­tem where de­vel­op­ers of nov­el an­tibi­otics can win a vouch­er that can then be used to ex­tend the ex­clu­siv­i­ty of an­oth­er drug for a pe­ri­od of time, or sold to an­oth­er com­pa­ny, there­by pay­ing for the an­tibi­ot­ic re­search.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER